Patient preferences for advanced therapies in ulcerative colitis using conjoint analysis.

Area of Science:

• Gastroenterology
• Pharmacoeconomics
• Patient-reported outcomes

Background:

• Selecting optimal advanced therapies for ulcerative colitis (UC) is challenging due to numerous treatment options.
• Understanding patient preferences is crucial for effective shared decision-making in UC management.

Purpose of the Study:

• To assess patient preferences for drug profiles in advanced therapy selection for ulcerative colitis (UC).
• To quantify the importance of various drug attributes and their utility levels based on disease severity.

Main Methods:

• A web-based conjoint analysis survey was conducted with 365 UC patients.
• Key drug attributes evaluated included administration route/frequency, onset speed, sustainability, safety risks, and novelty.
• Preferences were analyzed across mild and severe symptom scenarios, and for employed versus unemployed patients.

Main Results:

• Patient preferences for UC advanced therapies were highly individualized.
• Route/frequency of administration was the most important attribute in both mild and severe UC scenarios.
• Oral administration was preferred for mild symptoms; speed of onset was more valued in severe symptom scenarios.

Conclusions:

• Patient preferences for UC advanced therapies are influenced by disease severity and exhibit significant interindividual variability.
• Shared decision-making is essential to integrate patient perspectives when choosing advanced therapies for ulcerative colitis.